NEW DELHI – A recent acquisition by a leading Indian biotech company could spur drug development and clinical trials for treatments for brain and central nervous system diseases. The incidence of both ailments is on the rise. Read More
NEW DELHI – India's drug pricing regulator has withdrawn a series of guidelines that capped prices of diabetes, cardiovascular disease and asthma drugs. Read More
SHANGHAI – Sanofi SA, of Paris, has chosen a Shanghai address for its Asia Pacific R&D Hub. Its fifth hub, it will coordinate a complex research network across 12 Asian countries, and 50 collaborations pursuing the pharma's model of borderless, "open innovation." Read More
HONG KONG – Japanese scientists have identified a potent cell signaling mediator that could represent an important universal therapeutic target molecule for the development of effective new treatments for multiple myeloma (MM). Read More
SHANGHAI – European drug companies may find it hard to bend the ear of the Chinese government on their own. The country is large with numerous stakeholders to take into account as China undertakes its massive health care reform project. Read More
Four months ago, Takeda Pharmaceutical Co. Ltd. took an option to develop and commercialize MGD010, a preclinical asset developed in-house by Macrogenics Inc. that uses its Dual-Affinity Re-Targeting (DART) technology to simultaneously engage the B-cell surface proteins CD32B and CD79B, targeting autoimmune diseases. Read More
Wuxi Pharmatech (Cayman) Inc., of Shanghai, said it acquired contract research organization Xenobiotic Laboratories Inc. Financial terms were not disclosed. Read More
Astellas Pharma US Inc., part of Astellas Pharma Inc., of Tokyo, named Brian McLellan president of Astellas Pharma Technologies in the Americas region. Read More
